Does sacubitril/valsartan improve functional capacity compared to lifestyle intervention in patients with nonobstructive hypertrophic cardiomyopathy?
The SILICOFCM study is designed to evaluate the effect of sacubitril/valsartan versus lifestyle intervention on functional capacity and other markers in patients with nonobstructive hypertrophic cardiomyopathy.
The SILICOFCM study will provide novel evidence about the effect of sacubitril/valsartan or lifestyle intervention on functional capacity, clinical phenotype, injury and stretch activation markers, physical activity, and quality of life in patients with nonobstructive HCM.
Tafelmeier et al. (Tue,) studied this question.